A European CDMO offering end-to-end manufacturing of cell and gene therapies, from early development to commercial supply.

CELLforCURE by SEQENS is a Contract Development and Manufacturing Organisation (CDMO) specialising in Advanced Therapy Medicinal Products (ATMPs). Based in Les Ulis, France, the site spans over 10,000 m² and features seven GMP lines, 48 cleanrooms, dedicated labs for process development and quality control, and a track record spanning 15 years of CGT manufacturing. Formerly owned by LFB and Novartis, CELLforCURE became part of SEQENS in December 2023, combining its deep cell and gene expertise with SEQENS’s global infrastructure and investment capacity. The organisation is ANSM‑authorised and aligned with both EU and U.S. regulatory standards.

Key Products & Services:

GMP Manufacturing

• Seven modular, flexible GMP lines for autologous and allogeneic cell therapies including CAR-T, TILs, NK cells, MSCs, iPSCs, HSCs, and more.
• Annual output includes hundreds of therapeutic batches, with over 600 autologous commercial doses and 10,000 clinical vials produced to date.

Process & Analytical Development

• Dedicated 300 m² development lab for tech transfer, process optimisation, scale-up, equipment qualification, and analytical method development.

Quality Control & Release Testing

• In‑house QC lab (800 m²) supporting environmental controls, raw material testing, in‑process and final batch release, sterility, identity, potency, and stability testing.

End-to-End CDMO Services

• Complete offering from early-stage development through commercial production and supply chain management.

With its combination of state-of-the-art infrastructure, recognised regulatory authorisation, and a comprehensive service portfolio, CELLforCURE by SEQENS offers a compelling one‑stop CDMO solution for developers of advanced cell and gene therapies. Positioned both technologically and strategically at the heart of the European biotech ecosystem, it is well placed to support clinical pipelines and commercial manufacturing alike.